Dawn L. Hershman Announced as Candidate for ASCO Board of Directors

Dawn L. Hershman Announced as Candidate for ASCO Board of Directors

Dawn L. Hershman, MD, MS, FASCO, Professor of Medicine and Epidemiology at Columbia University and Deputy Director of the Herbert Irving Comprehensive Cancer Center, has been announced as a candidate for the American Society of Clinical Oncology (ASCO) Board of Directors in the Undesignated Member category.

The position carries a four-year term and represents an opportunity to contribute to the Society’s leadership, governance, and strategic priorities.

With a career spanning medical oncology, epidemiology, cancer research, academic leadership, and mentorship, Dr. Hershman brings extensive experience in both clinical medicine and the broader oncology community.

A longtime ASCO volunteer, she has held numerous leadership and advisory positions within the Society and has received two notable ASCO honors: the David Karnofsky Science of Oncology Award and the Women Who Conquer Cancer Mentorship Award.

Leading Oncology Research and Academic Medicine at Columbia University

Dr. Hershman is a tenured Professor of Medicine and Epidemiology at Columbia University College of Physicians & Surgeons.

She also serves as Chief of the Division of Hematology and Oncology and Deputy Director of the Herbert Irving Comprehensive Cancer Center at New York-Presbyterian/Columbia University Medical Center.

These appointments place her in senior leadership positions across clinical oncology, academic medicine, and cancer research.

Her background in both medicine and epidemiology reflects the importance of examining cancer not only through individual treatment decisions but also through broader questions surrounding patient outcomes, healthcare delivery, and population-level evidence.

At a time when oncology increasingly relies on real-world evidence, clinical research, and multidisciplinary collaboration, the integration of these perspectives remains an important part of advancing cancer care.

Dr. Hershman’s academic and institutional responsibilities connect these areas within a major academic medical center.

A Longstanding Commitment to ASCO

Dr. Hershman’s involvement with ASCO extends across numerous committees, working groups, and educational initiatives.

She currently serves as Co-Chair of the CDK Study Advisory Group, contributing to the Society’s activities in this area.

Her previous leadership appointments include serving as Chair of the ASCO Quality Care Symposium Planning Committee.

The Quality Care Symposium provides a platform for examining how cancer care is delivered, measured, and improved, bringing together clinicians, researchers, and healthcare professionals to discuss quality, patient outcomes, and healthcare systems.

Her role in the symposium’s planning reflects her involvement in an area of oncology that extends beyond the development of new treatments to examine the quality and effectiveness of care delivered to patients.

Dr. Hershman has also served on the ASCO Annual Meeting Education and Scientific Program Committees, participating in activities that support scientific exchange and continuing education across the oncology community.

Supporting the Next Generation of Cancer Researchers

Mentorship and research development have been important components of Dr. Hershman’s professional service.

She previously chaired the Conquer Cancer Foundation Grants Selection Committee, contributing to the processes through which research funding opportunities are evaluated.

Conquer Cancer, the ASCO Foundation, supports oncology research and professional development through grants and awards intended to advance cancer science and support investigators at different stages of their careers.

Dr. Hershman has also served as an IDEA Mentor, participating in ASCO’s efforts to support the professional development of emerging oncology professionals.

Her involvement in these initiatives reflects a commitment to the academic and professional development of the next generation of cancer researchers and clinicians.

In addition, she is a graduate of ASCO’s Leadership Development Program, which supports the development of leadership skills among oncology professionals.

Recognized for Scientific Contributions and Mentorship

Dr. Hershman’s contributions to oncology have been recognized through two significant ASCO awards.

She received the David Karnofsky Science of Oncology Award, an honor recognizing outstanding contributions to cancer research and the advancement of oncology.

Named after David A. Karnofsky, a pioneer in cancer chemotherapy and clinical oncology, the award acknowledges individuals whose scientific work has made an important contribution to the field.

Dr. Hershman has also received the Women Who Conquer Cancer Mentorship Award, recognizing her contributions to mentorship and the professional advancement of women in oncology.

These honors acknowledge two distinct but closely connected aspects of an academic oncology career: advancing scientific knowledge and supporting the individuals who will contribute to future discoveries.

Together, they reflect the breadth of Dr. Hershman’s involvement in oncology research, education, and professional development.

From Clinical Guidelines to Oncology Policy

Beyond her committee leadership and mentorship activities, Dr. Hershman has participated in numerous ASCO working groups, clinical guidelines, and policy statements.

These activities are central to the Society’s work in translating scientific evidence into professional recommendations and addressing issues that influence oncology practice.

Clinical guidelines support evidence-based decision-making, while policy statements provide a framework for examining broader matters affecting cancer care, healthcare professionals, and patients.

Her involvement across these initiatives demonstrates experience with both the scientific and organizational dimensions of oncology.

This combination of academic leadership, research expertise, and professional service is particularly relevant to the responsibilities of the ASCO Board of Directors.

A Broad Perspective on Oncology Leadership

The Undesignated Member position on the ASCO Board of Directors is not reserved for a single oncology specialty, allowing candidates to bring perspectives from different areas of cancer medicine and professional practice.

Dr. Hershman’s background encompasses clinical oncology, epidemiology, institutional leadership, quality of care, research funding, mentorship, and professional policy development.

Her previous ASCO appointments have involved scientific programming, educational initiatives, research grant evaluation, and advisory activities.

These experiences provide a foundation for participation in the Society’s governance and discussions concerning its future priorities.

The Next Chapter in ASCO Leadership

Dr. Hershman’s candidacy for the four-year Board of Directors term represents a potential new chapter in her longstanding service to ASCO.

From her leadership roles at Columbia University and the Herbert Irving Comprehensive Cancer Center to her involvement in ASCO committees, research initiatives, and mentorship programs, her career has connected scientific research with clinical care and professional development.

Her recognition through the David Karnofsky Science of Oncology Award and the Women Who Conquer Cancer Mentorship Award further highlights her contributions to both cancer science and the oncology community.

If elected, Dr. Hershman would bring this experience to the ASCO Board of Directors, contributing to the Society’s governance and its continued work in cancer research, education, and patient care.

The election will determine the next representative for the Undesignated Member seat as ASCO prepares for its upcoming leadership term.

Discover more articles like this on OncoDaily.

Vahe Grigoryan
Fact checked by Vahe Grigoryan MD, Editorial Director
Vahe Grigoryan
Medically reviewed by Vahe Grigoryan MD, Editorial Director